LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Listă Acțiuni・uniQure NV

uniQure NV

Închisă

26.7 -4.91

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

26.23

Maxim

28.08

Indicatori cheie
By Trading Economics
Venit	-16M -54M
Vânzări	-2M 3.6M
EPS	-0.73
Marjă de profit	-1,502.948
Angajați	221
EBITDA	13M -36M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+49.22% upside

Dividende
By Dow Jones
Următoarele câștiguri	28 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	476M 1.8B
Deschiderea anterioară	31.61
Închiderea anterioară	26.7

uniQure NV Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

2 mar. 2026, 13:13 UTC

Principalele dinamici ale pieței

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 ian. 2026, 15:14 UTC

Principalele dinamici ale pieței

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 nov. 2025, 13:34 UTC

Principalele dinamici ale pieței

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 sept. 2025, 18:51 UTC

Câștiguri

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Comparație

Modificare preț

uniQure NV Așteptări

Obiectiv de preț

By TipRanks

49.22% sus

Prognoză pe 12 luni

Medie 42.11 USD 49.22%

Maxim 95 USD

Minim 14 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruuniQure NV - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor uniQure NV - Dist în ultimele 3 luni.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.